Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02991209
Other study ID # 010815Testis
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date November 2016
Est. completion date June 2019

Study information

Verified date March 2020
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall purpose of the study is to evaluate the effect of 12 months testosterone replacement therapy in testicular cancer survivors with mild Leydig Cell Insufficiency in order to reduce the risk of cardiovascular disease.

The primary study objective is to evaluate changes in insulin sensitivity. The secondary study objective is to evaluate changes in the prevalence of metabolic syndrome, body composition, systemic inflammation and symptoms of testosterone deficiency.


Description:

This is a single-center, randomized, double-blind, placebo-controlled intervention study, designed to evaluate the effect of testosterone replacement therapy in testicular cancer survivors with mild Leydig Cell Insufficiency.

70 subjects will be randomized to receive either testosterone replacement therapy or placebo. The subjects will be invited for an information meeting where informed consent is signed. If a subject is suitable for participation in the trial, subject will be randomized to testosterone replacement therapy or placebo and baseline investigations will be performed. Afterwards, a 52-weeks treatment period begins in which subjects receive a daily dose of testosterone or placebo. Dose adjustment will be made three times during the first 8 weeks of the study. Evaluation of primary and secondary endpoints will be performed after 26 weeks, at the end of treatment (52 weeks) and three months after completion of treatment (week 64).


Recruitment information / eligibility

Status Completed
Enrollment 69
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Signed informed consent.

- Previous treatment for testicular cancer.

- No signs of relapse 1 year after last treatment (orchiectomy, radiotherapy, chemotherapy).

- Free testosterone < the age-adjusted median and > -2 standard deviations (SD) from the age-adjusted median and LH > 2 SD from the age-adjusted median.

Exclusion Criteria:

- Treatment with testosterone within the last 6 months.

- Contraindications to testosterone treatment (prostate cancer, prostate specific antigen (PSA)> 4 ng/mL), malignancy suspect prostate by digital rectal examination, Alanine aminotransferase (ALT)> 1.5 upper reference level, Erythrocyte Volume Fraction (EVF) > 50%.

- Breast cancer.

- Symptomatic obstructive sleep apnoea syndrome

- Heart failure > NYHA II.

- Uncontrolled hypertension: (Systolic blood pressure > 160 mm Hg despite antihypertensive treatment, measured at two separate occasions)

- Inability to understand information about the trial

- Participation in any other clinical trial

- Allergy for the active substance or additives in Tostran or placebo.

- Known diabetes mellitus, or diabetes mellitus detected at screening or baseline tests.

Study Design


Intervention

Drug:
Testosterone

Placebos


Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Mikkel Bandak

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in insulin sensitivity Evaluation of changes in two hours plasma glucose investigated by Oral Glucose Tolerance Test (OGTT) 1 year
Secondary Changes in fasting plasma lipids between baseline and 52 weeks 1 year
Secondary Changes in BMD and fat percent between baseline 52 weeks BMD and body composition evaluated by DXA-scan 1 year
Secondary Changes in systemic inflammation between baseline and 52 weeks Analysis of tnf-alfa, interleukine 1-beta, interleukine 1, interleukine 6, interleukine 8 1 year
Secondary Changes in plasma-adipocytokines between baseline and 52 weeks 1 year
Secondary Changes in fasting plasma glucose between baseline and 52 weeks 1 year
Secondary Changes in Quality of life between baseline and 52 weeks. EORTC-QLQ C30 1 year
Secondary Adverse events evaluated by the Common Terminology Criteria for Adverse Events Version 4.0 1 year
Secondary Changes in prevalence of metabolic syndrome between baseline and 52 weeks According to NCEP-ATPIII criteria 1 year
Secondary Changes in haemoglobin A1c between baseline and 52 weeks 1 year
Secondary Changes in plasma insulin between baseline and 52 weeks 1 year
Secondary Changes in fatigue between baseline and 52 weeks MFI-20 (Multidimensional Fatigue Inventory) 1 year
Secondary Changes in Anxiety and depression between baseline and 52 weeks HADS (Hospital Anxiety and Depression Scale) 1 year
Secondary Changes in Symptoms of low levels of testosterone, erectile dysfunction between baseline and 52 weeks IIEF-15 (International Index of Erectile Dysfunction) 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A